NCT06294275 - A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

January 2, 2024

Study Completion Date

April 6, 2024

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

BIOLOGICAL

LP-001 Dose 1 (Single)

A single dose of LP-001 (Dose 1) was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 2 (Single)

A single dose of LP-001 (Dose 2) was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 3 (Single)

A single dose of LP-001 (Dose 3) was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 4 (Single)

A single dose of LP-001 (Dose 4) was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 5 (Single)

A single dose of LP-001 (Dose 5) was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 6 (Single)

A single dose of LP-001 (Dose 6) was administered subcutaneously.

BIOLOGICAL

Placebo (Single)

A single dose of placebo was administered subcutaneously.

BIOLOGICAL

LP-001 Dose 7 (Multiple)

LP-001 (Dose 7) was administered multiple times subcutaneously.

BIOLOGICAL

LP-001 Dose 8 (Multiple)

LP-001 (Dose 8) was administered multiple times subcutaneously.

BIOLOGICAL

Placebo (Multiple)

Placebo was administered multiple times subcutaneously.

Trial Locations (1)

Shanghai Public Health Clinical Center, Shanghai